Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer
    Meeting Abstract

    Yap, T. A.; Elhaddad, A. M.; Grisham, R. N.; Hamm, J. T.; Marks, D. K.; Shapiro, G.; Le Corre, C.; Li, J.; Lin, T. T.; Liu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors
    Meeting Abstract

    Drilon, A. E.; Johnson, M. L.; Gadgeel, S. M.; Nepert, D.; Feng, G.; Golmakani, M.; Reddy, M.; Harney, A.; Oliver, C.; Mills, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Meeting Abstract

    Barker, C. A.; D'Angelo, S. P.; Steckler, A. M.; Lian, M.; Wasilewski, G.; Lacouture, M. E.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL)
    Meeting Abstract

    Locke, F. L.; Lekakis, L. J.; Eradat, H.; Munoz, J.; Tees, M. T.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S.; Popplewell, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer
    Meeting Abstract

    O'Reilly, E. M.; Wainberg, Z. A.; Weekes, C. D.; Furqan, M.; Kasi, P. M.; Devoe, C. E.; Leal, A. D.; Chung, V.; Perry, J.; Seenappa, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors
    Meeting Abstract

    Li, B. T.; Pegram, M. D.; Lee, K. W.; Sharma, M.; Lee, J.; Spira, A. I.; Hanna, G. J.; Kang, Y. K.; Rasco, D. W.; Moore, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting CD47 in lymphoid malignancies with CAR T cells
    Meeting Abstract

    Boardman, A. P.; James, S.; Van Den Brink, M. R. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
    Meeting Abstract

    Lazaratos, A. M.; Maritan, S. M.; Darlix, A.; Ratosa, I.; Ferraro, E.; Griguolo, G.; Pellerino, A.; Hofer, S.; Jacot, W.; Stemmler, H. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Large-scale clinicogenomic models of solid tumor CNS metastasis
    Meeting Abstract

    Jee, J.; Luthra, A.; Fong, C.; Pichotta, K.; Tran, T.; Altoe, M.; Miller, A.; Shen, R.; Berger, M. F.; Sanchez-Vega, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save